BrainCool AB (BRAIN) Fair Value & Analysis
Healthcare · SE · Market cap 301M SEK
Fair value as of: Jun 24, 2026
Analysis
BrainCool AB (BRAIN) currently trades at kr 0.7200, while our model-based Fair Value estimate is kr 1.34 — implying the stock looks roughly 86.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers BrainCool system, a system to monitor and control a patient's temperature to anatomical zones for head/neck, thighs, and torso. It also offers RhinoChill system, a portable and battery-powered cooling product to spray liquid coolant for patient's nostrils with a catheter; Cooral system provides medical professionals a way to reduce the risk of oral mucositis; and IQool system, a temperature management system that monitors and controls a patient's temperature. In addition, the company provides products for medical cooling treatments for diseases, including stroke, cardiac arrest, migraine, and oral mucositis. BrainCool AB (publ) was incorporated in 2010 and is based in Lund, Sweden.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is BrainCool AB (BRAIN) undervalued?
What is the fair value of BRAIN?
What is the quality score of BRAIN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.